Search or
𝛼SK
𝛼SKbullish
Biocon Ltd - Resilient Momentum in Biosimilars Driving Growth
Biocon reported an in-line performance for Q2FY26, with revenue rising 19.6% YoY and 9% QoQ to Rs 4,296 Cr, driven by strong traction in biosimilars (up 24.7% YoY) and generics (up 24.7% YoY).
What is covered in the Full Insight:
- Operational Performance
- CRDMO Business Update
- R&D Investments and Pipeline Progression
- Balance Sheet Strengthening and Outlook
- Valuation & Recommendation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x